Expert Interviews

John Kirkwood, MD, PhD, addresses the idea of pseudoprogression seen in melanoma therapy.

An expert in melanoma cancer treatment relays the monitoring options for melanoma therapy and gives advice for how long these therapies should be monitored.

CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to discuss the benefit of treatment with daratumumab, carfilzomib, lenalidomide, and dexamethasone and the population of patients with newly diagnosed myeloma who will best benefit from treatment.

Scott Tagawa, MD, MS, detailed 2 presentations from ESMO’s presidential symposium that he thinks will have an impact on treating patients with metastatic castration-sensitive prostate cancer.

Roy S. Herbst, MD, PhD, reviews indicators of relapse or progression of disease when monitoring patients on therapy in NSCLC.

Roy S. Herbst, MD, PhD, provides insight on selecting the optimal therapy for non–small-cell lung cancer and shares considerations for the use of combination chemotherapy and immunotherapy.

CancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology to talk survival and progression outcomes from the CARD trial in patients with metastatic castration-resistant prostate cancer.

An expert oncologist discusses the biomarker testing targets in metastatic prostate cancer.

Oliver Sartor, MD, describes the different tests routinely ordered for metastatic prostate cancer.

CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about minimal residual disease and its importance in the treatment of multiple myeloma.

A panel of hematologists/oncologists conclude a discussion about transplant-ineligible multiple myeloma (MM) by reacting to current treatment gaps that need to be addressed.

Experts Alexander Spira, MD, PhD, FACP, and D. Ross Camidge, MD, PhD, share insight and key takeaways from the eNRGy1 global registry study.

Drs Liliana Bustamante and Richard Kim explore conclusions highlighted by a paper on postoperative MRD analysis as a strong prognostic biomarker in colorectal cancer.

Drs Cesar Perez and Victoria Meucci Villaflor review “Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations” by Ho AL, et al.

Experts review the case of a 75-year-old woman with newly diagnosed multiple myeloma and discuss treatment selection, continuation, reduction, and duration.

In-depth considerations for available frontline therapy regimens for patients with transplant-ineligible multiple myeloma.

CancerNetwork® sat down with Edward B. Garon, MD, at the 2021 World Conference on Lung Cancer to talk about key findings with datopotamab deruxtecan therapy in patients with non–small cell lung cancer and other ongoing trials.

CancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology to discuss how a hypothetical cohort from the CARD trial highlighted the impact of treatment with cabazitaxel on costs and complications in patients with metastatic castration-resistant prostate cancer.

Recommendations when talking with patients with transplant-ineligible multiple myeloma (MM) who request to stop receiving treatment.

Dr John Kirkwood discusses physician considerations that are examined before immunotherapy use in the treatment of melanoma.